Your partner's labs came back fine. The doctor said so in a visit of about eight minutes, suggested fewer carbs and booked nothing further. You have watched the 3 AM waking, the fog that follows into the workday and the weight that keeps arriving anyway. Now you are reading before you say anything, because you want to know exactly what you would be suggesting and what it would cost.
Chris and Dana, the couple in this piece, are a composite. Neither is a real patient. No result described here belongs to anyone. We follow Dana through her first three months with GoodLife Health and say at each step what a clinician would check and why. GoodLife Health is a labs-first membership. It draws nine biomarkers four times a year and puts every result in the member's hands. A clinician then treats what the results show.
- A normal result places a number inside a population range. It does not show where that number is heading.
- Every quarterly panel includes Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP and Fasting Insulin. Ask whether your partner's last panel did.
- The first three months bring two panels, a long first visit, messages between visits and a written protocol.
- Medication, when a clinician finds it indicated, goes to your partner's own pharmacy at that pharmacy's price.
- The membership is $299 a month and pairs with insurance. It does not replace it.
- The decision belongs to your partner. This piece gives you the facts to raise it.
The sentence you both heard
Chris noticed before Dana said anything. Dana used to be the one in the house who remembered every school form and every deadline. Now she rereads the same email twice before a meeting. She wakes at 3 AM most nights and lies there until the alarm. Her clothes have gone up a size. No change she has made at lunch has moved that.
She went to her doctor. The visit was short and the panel was basic. That night at dinner she repeated the sentence she had been given: “My labs are normal.”
Chris heard relief in the sentence and something closer to resignation. Dana had taken the result as permission to stop asking. When Chris raises it now, she gives the answer most people give in her place: “Do I need labs? My doctor says mine are fine.” It is a fair question. She also has a GP she likes and a calendar with no room in it. Those are the three objections Chris would have to meet. Chris wants to meet them with facts.
If this is your situation, you are probably doing what Chris did. You are reading before speaking. The person you love has been dismissed once already. You do not want to be the second person to suggest that something is wrong. That instinct is kind. It is also right, because a suggestion made with the facts in hand is easier to hear than a worry.
Nobody here thinks Dana's doctor was careless. A short visit is built to screen. A workup takes longer and usually needs more than one draw. The visit answered the question it was built for, which is whether any number on a basic panel fell outside its range. It did not ask where those numbers were heading. It did not ask which numbers were never drawn. Those two questions are the subject of the rest of this piece.
What a normal result can and cannot tell you
A reference range describes where most people's results fall. When a report says normal, it means your partner's number sits inside that band. That is worth knowing. It does not say whether the number suits Dana. It does not say which way the number is moving. Normal is a population range. Dana is one person.
The national data show how far apart those two ideas can be. Our definitive guide to Cardiometabolic Optimization cites NHANES data from 2009–2016 showing that only 12% of US adults met the criteria for optimal metabolic health. That figure measures health. A reference range measures where people fall. A routine report shows only the second.
The first gap, then, is the range. The second is the list of markers. The direction of cardiometabolic medicine is testing before treating, with ApoB read where LDL once stood alone and fasting insulin read where glucose once stood alone. Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP look at heart risk beyond LDL. Fasting insulin matters because it can be measured before glucose turns abnormal. Dana does not yet know which of these her panel included. She heard her result as a sentence and never saw the page.
The guide describes why these markers belong in one reading: insulin resistance drives weight gain, visceral fat disrupts hormones and disrupted hormones stall metabolism. A panel that reads one link of that chain cannot see the others. The 3 AM waking, the fog and the weight may belong to one picture. They may not. A clinician can tell only by reading the markers side by side.
The third gap is time. One draw tells you where a number sat on one morning. Hormone and metabolic markers can change without symptoms, which is why a single result cannot show whether things are getting better or worse. Two results can.
A normal result tells you where a number sits among other people and nothing about where it is going.
A result inside the reference range describes where a number sat on the day it was drawn. A repeat draw on the same markers is what shows which way it is moving.
We do not know what Dana's panel will show. It may confirm what her doctor said. If it does, she will have a baseline on the markers that matter for these questions and a clinician who reads the next panel against it. That is a result too. It is worth having.
Dana's first three months, step by step
Here is what would happen, in order. The membership tests first and treats second. Every panel goes into Dana's hands. Medication comes only if a clinician finds it indicated.
The first three months at a glance
| Stage | What happens | Why it is there |
|---|---|---|
| Before month one | Eligibility check, intake, checkout and a clinician's review | A clinician decides whether to accept Dana into care |
| Month one | The first panel, then the first video visit | The visit starts with her results |
| Months one to three | Messages with the care team and a written protocol | Questions are answered between visits |
| Month three | The second panel and a review | Two results show a direction |
Before month one: the check and the review
The path begins with the eligibility check, which Dana completes herself. The intake and the checkout follow. At checkout, $598 is held on her card to cover the first two months. It is a hold and is charged only once a clinician accepts Dana into care. If the clinician cannot accept her, the hold is released and she is never charged. Once she is accepted, the first two months are charged and are non-refundable.
Not everyone is accepted. The review is where a clinician first reads Dana's history and decides whether to take her on as a patient. That decision belongs to the clinician, which is how it should be.
Month one: the first panel
Before the first visit, Dana goes to a local lab for a blood draw. This is the Biomarker Audit, the same cardiometabolic panel she would repeat every 90 days, four times a year. It includes Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP, Fasting Insulin, Hemoglobin A1c (HbA1c), TSH With Reflex To Free T4 and more. Every result comes back to Dana. She can share the results with Chris or with her GP as she chooses.
Each marker answers a question a basic panel may not have asked. Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP give a view of heart risk that LDL alone does not. Fasting Insulin is read beside Hemoglobin A1c (HbA1c) because insulin can move before glucose turns abnormal. Her thyroid is read in the same panel every quarter, so it is never left out of the picture.
Month one: the first visit
The first visit is by video, with the results already in. Our walkthrough of what a direct primary care visit actually looks like puts a typical first visit at 45 to 60 minutes. The clinician goes through each marker with Dana and explains how it connects to what she has been feeling. She can bring every concern at once, from the 3 AM waking to the fog in meetings. Nobody asks her to book a second appointment for a second complaint.
The visit ends with a written protocol. It says what to do now and what to message about if something changes. It also says which markers to recheck and when. If a medication is indicated, the clinician prescribes branded, FDA-approved medication to the pharmacy Dana chooses, at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on it. Nothing in this scenario assumes Dana needs medication at all. If the panel points somewhere else, the protocol says so.
If a GLP-1 were ever indicated, the cost would be the pharmacy's. The manufacturers publish their own self-pay prices. In September 2026, NovoCare listed Wegovy pens at $199 a month for the first two fills (an introductory offer for new patients through December 2026) and $349 a month after. LillyDirect listed Zepbound vials at $299 to $449 a month depending on dose. Whether insurance covers any medication is between Dana, her plan and her pharmacy. Nobody here promises that it will. The membership fee stays $299 whatever is prescribed and whatever the dose.
Between visits
Between visits, Dana can message the care team with whatever comes up. Video visits are part of the fee as well. This is the honest answer to her calendar. Each quarter asks for one blood draw and a review of the results. The walkthrough puts a typical follow-up visit at 20 to 30 minutes. Messages fit into whatever minute she has.
Month three: the second panel
About 90 days after the first draw, Dana repeats the same panel. This is the step a once-a-year visit cannot give her. Her clinician now has two results for each marker and can see which way each one is moving. The protocol is adjusted to what the numbers show. If nothing has moved and nothing needs to, the clinician says so plainly.
The guide explains that the first two months are what the diagnostic foundation takes to build, which is why the commitment is two months. From month three, the membership is month to month at $299.
What it costs and what it does not do
The membership is $299 a month. Over a year, that is $3,588. It pairs with insurance for catastrophic coverage and does not replace it. The family's plan stays in place for the hospital and for specialists. The membership replaces the primary-care relationship for cardiometabolic care. It is precision direct primary care for that one system. It is not full-scope primary care. If Dana's GP is the person she sees for a sprained ankle, nothing here asks her to change that.
The membership promises no outcome. No weight loss is guaranteed and no medication is promised. What it does promise is the work, meaning the panels, the clinician who reads them and the protocol that follows from them.
There are faster ways to get a prescription. An app at $99 a month can write one quickly. When a company earns on the drug, the drug becomes the product. GoodLife Health sells neither the drug nor the dose, so what it sells is the clinical work of finding out what is going on. At the other end of the market, a concierge practice can cost $20,000 a year. The membership sits between the two, with quarterly labs and a clinician who stays.
How to raise it this week
Whether or not Dana ever joins, Chris can do four useful things this week.
- Ask Dana whether she would request the full report from her last draw. The printed page shows exactly which markers were drawn.
- Look on it for Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP and Fasting Insulin. If they are missing, her doctor can say whether they can be ordered and what they would cost.
- Keep a short note of the 3 AM waking and the fog, with dates. Any clinician can do more with dates than with impressions.
- Raise it as a request for more information. Her doctor can be right about the basic panel while the rest of the picture is still unread.
When Chris does raise it, the three objections have plain answers. Dana may need markers her doctor never ordered. Only her report can say. She can keep her GP. Her calendar needs one blood draw and one review a quarter, with messages whenever she wants them.
Who this is not for
This membership is the wrong choice for someone who wants a prescription this week without a blood draw. It is wrong for anyone who will not repeat a panel every 90 days, because the second panel is where the value is. It does not cover every kind of primary care. It does not replace insurance. It is wrong for anyone who wants a promised result, since none is offered. It is open only to people who live in one of the 50 states. It is also not for Dana if Dana does not want it. Chris can bring the facts. The decision is hers.
If none of that describes your partner, here is the offer in full. The membership is $299 a month. At sign-up, $598 is held on the card for the first two months and is charged only once a clinician accepts the patient into care. If the clinician cannot accept the patient, the hold is released and nothing is charged. Once the patient is accepted, the first two months are non-refundable. From month three, it is month to month. The fee buys four cardiometabolic panels a year with every result in the patient's hands, a clinician who stays, video visits and messages between visits. Medication, when indicated, goes to the patient's own pharmacy at that pharmacy's price. GoodLife Health takes nothing on it. What the membership returns is the diagnosis an eight-minute visit never produced, the same markers followed over time and no repeat of that eight-minute visit. It tests first and treats second. It sells neither the drug nor the dose. For Dana, the reason to start now is the week Chris has already described. She is still waking at 3 AM. A routine check comes once a year. Three months from now, she could have two readings of every marker and a clinician who knows what they mean.
Related Reading
- Cardiometabolic Optimization: The Definitive Guide
- What a Direct Primary Care Visit Actually Looks Like (2026)
References
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings